Viracta Therapeutics (VIRX) PT Lowered to $4 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Viracta Therapeutics, Inc. (VIRX) Tops Q2 EPS by 12c
August 14, 2024 8:04 AM EDTViracta Therapeutics, Inc. (NASDAQ: VIRX) reported Q2 EPS of ($0.25), $0.12 better than the analyst estimate of ($0.37).
For earnings history and earnings-related data on Viracta Therapeutics, Inc. (VIRX) click here.
... MoreViracta Therapeutics (VIRX) Reports Positive Data from the Phase 2 NAVAL-1 Trial
August 14, 2024 7:00 AM EDTViracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today reported positive Phase 2 NAVAL-1 trial results from Stages 1 and 2 of the relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) peripheral T-cell lymphoma (PTCL) cohort. Additionally, the Company received productive feedback from its meeting with the U.S. Food and Drug Administration (FDA), providing clarity on the potential regulatory path to initial registration of Nana-val in patients with R/R EBV+ PTCL. Based on FDAs feedback, Viracta plans to begin... More
